Clinical Trials Logo

Urothelial Carcinoma Recurrent clinical trials

View clinical trials related to Urothelial Carcinoma Recurrent.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05874921 Recruiting - Clinical trials for Urothelial Carcinoma

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

uTRACT
Start date: November 17, 2023
Phase:
Study type: Observational [Patient Registry]

The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.

NCT ID: NCT05375903 Recruiting - Bladder Cancer Clinical Trials

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Start date: June 1, 2022
Phase: Phase 1
Study type: Interventional

This study is being conducted to evaluate the safety and determine the recommended Phase 2 dose (RP2D) of UGN-301 (zalifrelimab) administered intravesically as monotherapy and in combination with other agents in patients with recurrent NMIBC.

NCT ID: NCT05027412 Recruiting - Bladder Cancer Clinical Trials

En Bloc TURBT With Collins Loop vs Conventional TURBT

TURBT
Start date: April 1, 2021
Phase: N/A
Study type: Interventional

This is a prospective, randomized, randomized and single-blind study in patients diagnosed with primary bladder CV. Patients diagnosed by cystoscopy of a bladder tumor and with indication for endoscopic surgical treatment, who meet the inclusion criteria, and who sign the Informed Consent (IC), will be randomized.

NCT ID: NCT03914794 Recruiting - Bladder Cancer Clinical Trials

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Start date: October 2, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well Pemigatinib (an orally administered inhibitor of fibroblast growth factor receptors 1, 2, and 3) works in non-muscle invasive bladder cancer (NMIBC) patients with recurrent tumors and a prior history of low- or intermediate-risk NMIBC tumors. Participants will receive pemigatinib for 4-6 weeks prior to standard of care transurethral resection of bladder tumor (TURBT).